12:00 AM
 | 
Jul 30, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Human cytomegalovirus (CMV) type 2 membrane protein (UL50); CMV type 3 membrane protein (UL53)

Infectious disease

INDICATION: Cytomegalovirus (CMV)

In vitro studies suggest disrupting UL50-UL53 binding could help treat CMV infection. Mutagenesis of UL50 followed by an in vitro UL50-UL53 binding assay identified three mutant forms of the...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >